RAVENSBURG, Germany -- (BUSINESS WIRE) -- Vetter has announced significant progress in its solution for state-of-the-art product packaging, designed to support the prevention of product counterfeiting. This innovative development is in response to expanded requirements by official regulatory agencies that require manufacturers to have clear identification of drugs on packaging. Vetter is successfully implementing its IT-solution and will offer its customers a range of serialization services as a basis for track-and-trace programs by the end of 2014.
Drug counterfeiting is a serious problem facing the industry and continues to grow unabated worldwide. To combat this issue, regulatory agencies have been seeking and implementing new methods to thwart the counterfeiters. Serialization of packaging has been considered one of the most effective solutions so far by many countries. The USA, South Korea, and Brazil as well as regions including the European Union will be following suit in the coming years.
In this regard, Vetter, a contract development and manufacturing organization (CDMO) with extensive packaging experience, has designed an effective solution for its customers: a flexible serialization service, that forms the basis of track-and-trace programs. With this offer, the company is extending its existing services. These services include, for example, printing of Global Trade Item Numbers (GTIN) on packages, which has been requested by France and is expected to be requested by the USA in 2015. Following the successful implementation of an initial IT solution, Vetter began implementing an engineering platform for serialization that is expected to be operational by the end of 2014. The service will support pharmaceutical and biotech companies in implementing their own track-and-trace programs for a secured and controlled supply chain.
“The Vetter serialization service will support growing customer and regulatory demands in the area of track-and-trace in the struggle against counterfeiting," says Thomas Otto, Managing Director. “This service, which we expect to have implemented by late 2014, is based upon a comprehensive concept study that we undertook. Our serialization service will enable that packages include unique identification necessary to support product security and supply chain efficiency."
Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Its clientele includes the world’s top 10 pharma/biotech firms and emerging companies alike. A full-service provider, Vetter supports products throughout their lifecycles, from preclinical development through global market supply. Through its U.S. and European facilities, Vetter Development Service provides state-of-the-art support for early-stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. The company is the originator of dual-chamber technology, which enables easier, safer lyophilized-drug administration; and is a leader in the use of RABS technology in cleanrooms, which mitigates risk of product contamination during the manufacturing process. Headquartered in Ravensburg, Germany, the company employs approximately 3,300 staff across Europe and the United States. For more information about Vetter, visit www.vetter-pharma.com.